Фундаментальные аспекты биохимии селена и селенопротеинов: прикладное значение в онкологии

Цель исследования – провести систематический анализ данных, имеющихся в современной литературе об эссенциальности селена в биологических системах и значении селенопротеинов в онкогенезе.

Материал и методы. При подготовке обзора проведен поиск публикаций в информационных базах Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240). Для получения полнотекстовых документов использованы электронные ресурсы PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru.

Результаты. Необходимость применения соединений селена с целью профилактики и лечения злокачественных новообразований носит неоднозначный характер, а некоторые селенопротеины продемонстрировали пермиссивную роль в онкогенезе, что требует дальнейшего углубленного изучения вопроса.

Заключение. Необходимо продолжать комплексные молекулярные исследования биоорганических соединений селена на морфологическом, ультраструктурном и биохимическом уровнях при опухолях различных локализаций в зависимости от генетических особенностей изучаемой популяции и геохимических характеристик региона.

1. Kurokawa S., Berry M.J. Selenium. Role of the essential metalloid in health. Met Ions Life Sci. 2013; 13: 499–534. doi: 10.1007/978-94-007-7500-8_16.

2. Kozlov A.P. Evolution by Tumor Neofunctionalization: the role of tumors in the origin of new cell types, tissues and organs. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney and Tokyo: Academic Press/Elsevier; 2014. 248 p.

3. Elhodaky M., Diamond A.M. Selenium-Binding Protein 1 in Human Health and Disease. Int J Mol Sci. 2018; 19(11): 3437. doi: 10.3390/ijms19113437.

4. Ying Q., Ansong E., Diamond A.M., Yang W. A Critical Role for Cysteine 57 in the Biological Functions of Selenium Binding Protein-1. Int J Mol Sci. 2015; 16(11): 27599–608. doi: 10.3390/ijms161126043.

5. Minich W.B. Selenium Metabolism and Biosynthesis of Selenoproteins in the Human Body. Biochemistry (Mosc). 2022; 87(s1). doi: 10.1134/S0006297922140139.

6. Авцын А.П., Жаворонков А.А., Риш М.А., Строчкова Л.С. Микроэлементозы человека. М., 1991. С. 126–44.

7. Kieliszek M. Selenium. Chapter Eleven. Advances in food and nutrition research. 2021; 96: 417–29. doi: 10.1016/bs.afnr.2021.02.019.

8. Барановский А.Ю. Диетология. 5-е издание. СПб., 2017. 1104 с.

9. Wang P., Chen B., Huang Y., Li J., Cao D., Chen Z., Li J., Ran B., Yang J., Wang R., Wei Q., Dong Q., Liu L. Selenium intake and multiple health-related outcomes: an umbrella review of meta-analyses. Front Nutr. 2023; 10. doi: 10.3389/fnut.2023.1263853.

10. Rayman M.P. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005; 64(4): 527–42. doi: 10.1079/pns2005467.

11. Povey S., Lovering R., Bruford E., Wright M., Lush M., Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet. 2001; 109(6): 678–80. doi: 10.1007/s00439-001-0615-0.

12. Gladyshev V.N., Arnér E.S., Berry M.J., Brigelius-Flohé R., Bruford E.A., Burk R.F., Carlson B.A., Castellano S., Chavatte L., Conrad M., Copeland P.R., Diamond A.M., Driscoll D.M., Ferreiro A., Flohé L., Green F.R., Guigó R., Handy D.E., Hatfeld D.L., Hesketh J., Hoffmann P.R., Holmgren A., Hondal R.J., Howard M.T., Huang K., Kim H.Y., Kim I.Y., Köhrle J., Krol A., Kryukov G.V., Lee B.J., Lee B.C., Lei X.G., Liu Q., Lescure A., Lobanov A.V., Loscalzo J., Maiorino M., Mariotti M., Sandeep Prabhu K., Rayman M.P., Rozovsky S., Salinas G., Schmidt E.E., Schomburg L., Schweizer U., Simonović M., Sunde R.A., Tsuji P.A., Tweedie S., Ursini F., Whanger P.D., Zhang Y. Selenoprotein Gene Nomenclature. J Biol Chem. 2016; 291(46): 24036–40. doi: 10.1074/jbc.M116.756155.

13. Голубкина Н.А., Папазян Т.Т. Селен в питании: растения, животные, человек. М., 2006. 254 с.

14. Sword J.T., Pope A.L., Hoekstra W.G. Endotoxin and lipid peroxidation in vitro in selenium- and vitamin E-defcient and -adequate rat tissues. J Nutr. 1991; 121(2): 258–64. doi: 10.1093/jn/121.2.258.

15. Shreenath A.P., Hashmi M.F., Dooley J. Selenium Defciency. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

16. Burk R.F., Olson G.E., Hill K.E. Deletion of selenoprotein P gene in the mouse. Selenium: its molecular biology and role in human health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 111–122.

17. Варламова Е.Г., Гольтяев М.В., Новоселов С.В., Новоселов В.И., Фесенко Е.Е. Биосинтез и механизм встраивания селеноцистеина в синтезируемые белки. Молекулярная биология. 2013; 47(4): 558–67. doi: 10.7868/S0026898413040137.

18. Genchi G., Lauria G., Catalano A., Sinicropi M.S., Carocci A. Biological Activity of Selenium and Its Impact on Human Health. Int J Mol Sci. 2023; 24(3): 2633. doi: 10.3390/ijms24032633.

19. Seko Y., Saito Y., Kitahara J., Imura N. Active Oxygen Generation by the Reaction of Selenite with Reduced Glutathione in Vitro. In: Selenium in Biology and Medicine. Eds. Wendel A. Heidelberg. Springer, 1989: 70–73.

20. Кудрин А.В., Громова О.А. Микроэлементы в иммуннологии и онкологии. М., 2007. 544 с.

21. Chiu-Ugalde J., Theilig F., Behrends T., Drebes J., Sieland C., Subbarayal P., Köhrle J., Hammes A., Schomburg L., Schweizer U. Mutation of megalin leads to urinary loss of selenoprotein P and selenium defciency in serum, liver, kidneys and brain. Biochem J. 2010; 431(1): 103–11. doi: 10.1042/BJ20100779.

22. Русецкая Н.Ю. Гипотетическая связь между метаболизмом селена и углеводным обменом. Современные проблемы науки и образования. 2014; (2): 488.

23. Vinceti M., Filippini T., Del Giovane C., Dennert G., Zwahlen M., Brinkman M., Zeegers M.P., Horneber M., D’Amico R., Crespi C.M. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018; 1(1). doi: 10.1002/14651858.CD005195.pub4.

24. Kadkol S., Diamond A.M. The Interaction between Dietary Selenium Intake and Genetics in Determining Cancer Risk and Outcome. Nutrients. 2020; 12(8): 2424. doi: 10.3390/nu12082424.

25. Ursini F., Heim S., Kiess M., Maiorino M., Roveri A., Wissing J., Flohé L. Dual function of the selenoprotein PHGPx during sperm maturation. Science. 1999; 285(5432): 1393–6. doi: 10.1126/science.285.5432.1393.

26. Mustacich D., Powis G. Thioredoxin reductase. Biochem J. 2000; 346 Pt 1(Pt 1): 1–8.

27. Bianco A.C., Larsen P.R. Selenium, deiodinases and endocrine function. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 207–219. doi: 10.1007/0-387-33827-6_19.

28. Arteel G.E., Briviba K., Sies H. Protection against peroxynitrite. FEBS Lett. 1999; 445(2–3): 226–30. doi: 10.1016/s0014-5793-(99)00073-3.

29. Kioussi C., Whanger P.D. Selenoprotein W in development and oxidative stress. Selenium: Its Molecular Biology and Role in Human Health. Eds D.L. Hatfield, M.J. Berry, V.N. Gladyshev. 2nd ed. N.Y.: Springer, 2006. P. 135–140.

30. Gu Q.P., Beilstein M.A., Vendeland S.C., Lugade A., Ream W., Whanger P.D. Conserved features of selenocysteine insertion sequence (SECIS) elements in selenoprotein W cDNAs from fve species. Gene. 1997; 193(2): 187–96. doi: 10.1016/s0378-1119(97)00113-3.

31. Kuria A., Fang X., Li M., Han H., He J., Aaseth J.O., Cao Y. Does dietary intake of selenium protect against cancer? A systematic review and meta-analysis of population-based prospective studies. Crit Rev Food Sci Nutr. 2020; 60(4): 684–94. doi: 10.1080/10408398.2018.1548427.

32. Bösl M.R., Takaku K., Oshima M., Nishimura S., Taketo M.M. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci USA. 1997; 94(11): 5531–34. doi: 10.1073/pnas.94.11.5531.

33. Lener M.R., Scott R.J., Wiechowska-Kozłowska A., SerranoFernández P., Baszuk P., Jaworska-Bieniek K., Sukiennicki G., Marciniak W., Muszyńska M., Kładny J., Gromowski T., Kaczmarek K., Jakubowska A., Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat. 2016; 48(3): 1056–64. doi: 10.4143/crt.2015.282.

34. Jiang Z., Chi J., Li H., Wang Y., Liu W., Han B. Efect of chitosan oligosaccharide-conjugated selenium on improving immune function and blocking gastric cancer growth. Eur J Pharmacol. 2021; 891. doi: 10.1016/j.ejphar.2020.173673.

35. Augustyniak M., Galas A. Selenium dietary intake and survival among CRC patients. Int J Vitam Nutr Res. 2023; 93(6): 518–28. doi: 10.1024/0300-9831/a000768.

36. Wang Y., Fang W., Huang Y., Hu F., Ying Q., Yang W., Xiong B. Reduction of selenium-binding protein 1 sensitizes cancer cells to selenite via elevating extracellular glutathione: a novel mechanism of cancerspecifc cytotoxicity of selenite. Free Radic Biol Med. 2015; 79: 186–96. doi: 10.1016/j.freeradbiomed.2014.11.015.

37. Radomska D., Czarnomysy R., Radomski D., Bielawska A., Bielawski K. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity. Nutrients. 2021; 13(5): 1649. doi: 10.3390/nu13051649.

38. Brigelius-Flohé R., Kipp A.P. Glutathione Peroxidase 2, a Selenoprotein Exhibiting a Dual Personality in Preventing and Promoting Cancer. In Selenium. Its Molecular Biology and Role in Human Health, 4th ed. Springer International Publishing: New York, NY, USA, 2016; Chapter 38; P. 451–462. doi: 10.1007/978-3-319-41283-2_38.

39. Bertz M., Kühn K., Koeberle S.C., Müller M.F., Hoelzer D., Thies K., Deubel S., Thierbach R., Kipp A.P. Selenoprotein H controls cell cycle progression and proliferation of human colorectal cancer cells. Free Radic Biol Med. 2018; 127: 98–107. doi: 10.1016/j.freeradbiomed.2018.01.010.

40. Shamberger R.J., Rudolph G. Protection against cocarcinogenesis by antioxidants. Experientia. 1966; 22(2): 116. doi: 10.1007/BF01900187.

41. Clark L.C., Combs G.F. Jr., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., Davis L.S., Glover R.A., Graham G.F., Gross E.G., Krongrad A., Lesher J.L. Jr., Park H.K., Sanders B.B. Jr., Smith C.L., Taylor J.R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276(24): 1957–63.

42. Zyambo K., Kelly P., Kayamba V. Evaluation of the association between gastric cancer and plasma selenium in Zambian adults: a casecontrol study. Ecancermedicalscience. 2022; 16: 1351. doi: 10.3332/ecancer.2022.1351.

43. Zhu X., Pan D., Wang N., Wang S., Sun G. Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies. Biol Trace Elem Res. 2021; 199(12): 4439–46. doi: 10.1007/s12011-021-02574-9.

44. Bevinakoppamath S., Saleh Ahmed A.M., Ramachandra S.C., Vishwanath P., Prashant A. Chemopreventive and Anticancer Property of Selenoproteins in Obese Breast Cancer. Front Pharmacol. 2021; 12. doi: 10.3389/fphar.2021.618172.

45. Wang L., Wang J., Liu X., Liu Q., Zhang G., Liang L. Association between selenium intake and the risk of pancreatic cancer: a metaanalysis of observational studies. Biosci Rep. 2016; 36(5). doi: 10.1042/BSR20160345.

46. Gómez-Tomás Á., Pumarega J., Alguacil J., Amaral A.F.S., Malats N., Pallarès N., Gasull M., Porta M.; PANKRAS II Study Group. Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma. Environ Mol Mutagen. 2019; 60(8): 693–703. doi: 10.1002/em.22296.

47. Janowska M., Potocka N., Paszek S., Skrzypa M., Wróbel A., Kluz M., Baszuk P., Marciniak W., Gronwald J., Lubiński J., Zawlik I., Kluz T. An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer. Nutrients. 2022; 14(5): 958. doi: 10.3390/nu14050958.

48. Yang W., Diamond A.M. Selenium-binding protein 1 as a tumor suppressor and a prognostic indicator of clinical outcome. Biomark Res. 2013; 1(1): 15. doi: 10.1186/2050-7771-1-15.

49. Meng Q., Xu J., Liang C., Liu J., Hua J., Zhang Y., Ni Q., Shi S., Yu X. GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death Dis. 2018; 9: 1187. doi: 10.1038/s41419-018-1244-z.

50. Li M., Cheng W., Nie T., Lai H., Hu X., Luo J., Li F., Li H. Selenoprotein K mediates the proliferation, migration, and invasion of human choriocarcinoma cells by negatively regulating human chorionic gonadotropin expression via ERK, P38 MAPK, and Akt signaling pathway. Biol. Trace Elem. Res. 2018; 184(1): 47–59. doi: 10.1007/s12011-017-1155-3.

51. Zhang X.Y., Gao P.T., Yang X., Cai J.B., Ding G.Y., Zhu X.D., Ji Y., Shi G.M., Shen Y.H., Zhou J., Fan J., Sun H.C., Yang L.X,. Huang C. Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. Am J Transl Res. 2018; 10(11): 3567–78.

52. Hughes D.J., Kunická T., Schomburg L., Liška V., Swan N., Souček P. Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer. Nutrients. 2018; 10(11): 1812. doi: 10.3390/nu10111812.

53. Wang Y., Zhu W., Chen X., Wei G., Jiang G., Zhang G. Seleniumbinding protein 1 transcriptionally activates p21 expression via p53- independent mechanism and its frequent reduction associates with poor prognosis in bladder cancer. J Transl Med. 2020; 18(1): 17. doi: 10.1186/s12967-020-02211-4.

54. Song M., Kumaran M.N., Gounder M., Gibbon D.G., NievesNeira W., Vaidya A., Hellmann M., Kane M.P., Buckley B., Shih W., Caffrey P.B., Frenkel G.D., Rodriguez-Rodriguez L. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol. 2018; 150(3): 478–86. doi: 10.1016/j.ygyno.2018.07.001.

55. Hu Y.J., Chen Y., Zhang Y.Q., Zhou M.Z., Song X.M., Zhang B.Z., Luo L., Xu P.M., Zhao Y.N., Zhao Y.B., Cheng G. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997; 56(3): 331–41. doi: 10.1007/BF02785304.

56. Lanfear J., Fleming J., Wu L., Webster G., Harrison P.R. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive efects of selenium? Carcinogenesis. 1994; 15(7): 1387–92. doi: 10.1093/carcin/15.7.1387.

57. Goltyaev M.V., Maltseva V.N., Varlamova E.G. Expression of ERresident selenoproteins and activation of cancer cells apoptosis mechanisms under ER-stress conditions caused by methylseleninic acid. Gene. 2020; 755. doi: 10.1016/j.gene.2020.144884.

58. Shimada B.K., Swanson S., Toh P., Seale L.A. Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers. Biomolecules. 2022; 12(11): 1581. doi: 10.3390/biom12111581.

59. Kobayashi H., Yoshimoto C., Matsubara S., Shigetomi H., Imanaka S. A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer. Cancer Drug Resist. 2023; 6(3): 547–66. doi: 10.20517/cdr.2023.49.

60. Li Z., Ferguson L., Deol K.K., Roberts M.A., Magtanong L., Hendricks J.M., Mousa G.A., Kilinc S., Schaefer K., Wells J.A., Bassik M.C., Goga A., Dixon S.J., Ingolia N.T., Olzmann J.A. Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat Chem Biol. 2022; 18(7): 751–61. doi: 10.1038/s41589-022-01033-3.

61. Sekhar K.R., Hanna D.N., Cyr S., Baechle J.J., Kuravi S., Balusu R., Rathmell K., Baregamian N. Glutathione peroxidase 4 inhibition induces ferroptosis and mTOR pathway suppression in thyroid cancer. Sci Rep. 2022; 12(1). doi: 10.1038/s41598-022-23906-2.

62. Santesmasses D., Gladyshev V.N. Selenocysteine Machinery Primarily Supports TXNRD1 and GPX4 Functions and Together They Are Functionally Linked with SCD and PRDX6. Biomolecules. 2022; 12(8): 1049. doi: 10.3390/biom12081049.

63. Fu B., Meng W., Zeng X., Zhao H., Liu W., Zhang T. TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma. BioMed Res. Int. 2017. doi: 10.1155/2017/4698167.

64. Tuo L., Xiang J., Pan X., Gao Q., Zhang G., Yang Y., Liang L., Xia J., Wang K., Tang N. PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway. Front. Oncol. 2018; 8: 611. doi: 10.3389/fonc.2018.00611.

65. Delgobo M., Gonçalves R.M., Delazeri M.A., Falchetti M., Zandoná A., Nascimento das Neves R., Almeida K., Fagundes A.C., Gelain D.P., Fracasso J.I., Macêdo G.B., Priori L., Bassani N., Bishop A.J.R., Forcelini C.M., Moreira J.C.F., Zanotto-Filho A. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer. Free Radic Biol Med. 2021; 177: 58–71. doi: 10.1016/j.freeradbiomed.2021.10.020.

66. Robledinos-Antón N., Fernández-Ginés R., Manda G., Cuadrado A. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development. Oxid Med Cell Longev. 2019. doi: 10.1155/2019/9372182.